TSHA — Taysha Gene Therapies, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1806310 ·
Last close
$4.00
Market Cap
$1.30B
52W High
$7.30
52W Low
$3.45
ADV30
3,661,562
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -50,782,000 | -46,639,000 | 470,433,000 | 455,407,000 | 83,167,000 |
| Mar 2026 | 0 | — | -43,486,000 | -42,410,000 | 300,351,000 | 276,576,000 | 88,407,000 |
| Dec 2025 | 5,485,000 | — | -28,300,000 | -27,851,000 | 343,320,000 | 319,767,000 | 96,382,000 |
| Sep 2025 | 0 | — | -34,024,000 | -32,733,000 | 316,554,000 | 297,344,000 | 97,565,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-132,191,000
Investing CF
$-3,318,000
Financing CF
$275,719,000
CapEx
$-3,384,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.43
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-800,349,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-149,591,000
Pretax Income TTM
$-149,633,000
Interest Exp TTM
$42,000
Analysts
13
Yahoo Snapshot (yfinance, live)
Total Revenue
$5,485,000
EBITDA
$-163,298,000
Free Cash Flow
$-90,184,376
Enterprise Value
$968,544,704
Total Cash
$422,833,984
Total Debt
$54,592,000
Shares Out
326,045,530
Trailing EPS
$-0.42
Book Value
$1.09
ROE
-54.2%
ROA
-27.3%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 9,773,000 | -110,498,000 | -108,995,000 | 343,320,000 | 96,382,000 | 246,938,000 | -93,090,000 |
| Dec 2024 | 8,333,000 | -86,621,000 | -89,298,000 | 160,364,000 | 88,839,000 | 71,525,000 | -81,225,000 |
| Dec 2023 | 15,451,000 | -71,374,000 | -111,566,000 | 172,731,000 | 97,794,000 | 74,937,000 | -73,018,000 |
| Dec 2022 | 2,502,000 | -126,027,000 | -166,014,000 | 126,276,000 | 125,327,000 | 949,000 | -88,390,000 |
TTM Snapshot
Revenues TTM
$5,485,000
NetIncome TTM
$-149,633,000
OpCashFlow TTM
—
Assets (Latest)
$470,433,000
Forward EPS
$-0.39
Max Pain — expiry 2026-12-18
max pain strike: $2.50 · spot: $3.99 · call oi: 1,888 · put oi: 418
Expected Move to 2026-12-18:
±$1.10
(27.57%) —
implied range
$2.89 –
$5.09
· ATM straddle on $4.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NVAX | NOVAVAX INC | $1.31B | $7.96 | — |
| IMCR | Immunocore Holdings plc | $1.43B | $27.81 | — |
| MEOBF | MESOBLAST LTD | $1.48B | $1.14 | — |
| VOR | Vor Biopharma Inc. | $1.12B | $18.18 | — |
| MESO | MESOBLAST LTD | $1.55B | $11.91 | — |
News headlines (Yahoo Finance, 1h cache)
Taysha Gene Therapies, Inc. Q3 2026 Earnings Call Summary
2026-11-13 13:30 · Yahoo
Taysha (TSHA) Q3 2026 Earnings Call Transcript
2026-11-13 06:13 · Yahoo
Taysha Gene Therapies Q3 Earnings Call Highlights
2026-11-12 21:14 · Yahoo
Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-12 12:30 · Yahoo
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2026-11-06 13:00 · Yahoo
Taysha Gene Therapies to Release Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 12
2026-11-05 13:00 · Yahoo
Does Early Rett Trial Success Change The Bull Case For Taysha Gene Therapies (TSHA)?
2026-10-19 02:07 · Yahoo
Taysha Gene Therapies (TSHA) Stock May Be Above Fair Value On Book Value
2026-10-09 18:12 · Yahoo
Taysha Gene Therapies (TSHA) Faces A Split Valuation Debate, Is It Really 66% Below Fair Value?
2026-10-09 07:15 · Yahoo
Taysha Gene Therapies Inc (TSHA) (Q2 2026) Earnings Call Highlights: Rett Syndrome Program ...
2026-08-12 05:02 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.